Sort   by:  
 Page size 
MetabolomicsUntargeted metabolomics for triaging of cytochrome b inhibitors during Chagas’ disease drug discovery

Chagas’ disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is a potentially fatal condition for which new treatments are urgently needed. Due to the lack of validated drug targets, phenotypic screening followed by target deconvolution is the dominant approach in Chagas’ d...

2026-01-12 | MTBLS13510 | MetaboLights
TranscriptomicsTranscription profiling of human MCF-7 cells treated with proteasome inhibitor MG132 and either dexamethasone or 17b-estradiol
The objective of the study was to investigate the effect of proteasome inhibition on glucocorticoid and estrogen receptor regulated gene expression. Experiment Overall Design: MCF-7 cells were treated with proteasome inhibitor (MG132), dexamethasone, 17b-estradiol or MG132 plus dexamethasone or MG13...
ORGANISM(S): Homo sapiens 
2008-06-20 | E-GEOD-8383 | biostudies-arrayexpress
ProteomicsPTEN DEFICIENCY LEADS TO PROTEASOME ADDICTION, A NOVEL VULNERABILITY IN GLIOBLASTOMA
Glioblastoma (GBM) is the most common primary brain tumor in adults with a median survival of approximately 15 months, therefore, more effective treatment options for GBM are required. To identify new drugs targeting glioblastomas, we performed a high throughput drug screen using patient-derived neu...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2020-12-04 | MSV000086560 | MassIVE
TranscriptomicsSubunit-specific vs. non-selective proteasome modulation in limiting inflammation in experimental colitis
Inflammatory bowel disease (IBD), comprising CrohnM-BM-4s disease and Ulcerative colitis, is characterized by chronic relapsing inflammation of the gut. It has been shown that increased proteasomal activity is associated with the expression of immunoproteasomes, which enhances NF-kB activation and t...
ORGANISM(S): Mus musculus 
2010-07-06 | E-GEOD-18163 | biostudies-arrayexpress
TranscriptomicsSynergistic effects of TOR and proteasome pathways on the yeast transcriptome and cell growth
The experiments were designed to interrogate the genetic interaction relationship between the TOR signalling pathway and the UPS-proteasome pathway in gene expression and cell growth. Yeast cells (BY4742pdr5delta) were treated with the drug vehicle, MG132 (50uM), rapamycin (200ng/ml) or both drugs. ...
ORGANISM(S): Saccharomyces cerevisiae 
2013-05-24 | E-MTAB-1550 | biostudies-arrayexpress
TranscriptomicsSuppression of BRCA1 sensitizes to proteasome inhibitors in DNA repair-independent manner.
Germline and somatic mutations in BRCA1predispose to breast cancer. We found that proteasome inhibitors can selectively kill BRCA1-depleted cells. The toxic response involves a deregulation of the G1/S cell cycle checkpoint via hyperphosphorylation of RB1, 53BP1-mediated arrest at G2/M checkpoint, ...
ORGANISM(S): Homo sapiens 
2015-01-01 | E-GEOD-56280 | biostudies-arrayexpress
TranscriptomicssiRNA of human MCF7 cells incubated with proteasome inhibitors bortezomib or Argyrin A or proteasome activity and knocked down for proteosomal subunits
Reduction in the cellular levels of the cyclin kinase inhibitor p27kip1 are frequently found in many human cancers and correlate directly with patient prognosis. Specifically ubiquitin dependent proteasomal turnover has been shown to cause reduced p27 expression in many human cancers. We recently de...
ORGANISM(S): Homo sapiens 
2008-06-16 | E-GEOD-8565 | biostudies-arrayexpress
TranscriptomicsIncreased Protein Processing Gene Signature in HDACi-resistant cells predicts response to proteasome inhibitors.
Epigenetic modifying enzymes are commonly mutated in diffuse large B cell lymphoma (DLBCL). Importantly, genetics abnormalities lead to inactivation of HAT, which tilt the balance in favor of decreased protein acetylation in DLBCL cells. This suggests that protein acetylation regulation is an impor...
ORGANISM(S): Homo sapiens 
2016-06-01 | E-GEOD-58421 | biostudies-arrayexpress
TranscriptomicsDifferentiation of DLBCL induced by HDAC inhibitors is associated with sensitization to proteasome inhibition
Epigenetic modifying enzymes are commonly mutated in diffuse large B cell lymphoma (DLBCL), suggesting that epigenetic regulation is an important factor in DLBCL pathogenesis and a potential target for therapy. We developed resistant cell lines to histone deacetylase inhibitors (HDACi), one such ep...
ORGANISM(S): Homo sapiens 
2016-08-01 | E-GEOD-59308 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of human HEK293 cells treated with the proteasome inhibitor epoxomicin
The objective of this study is to identify the genes that are up-regulated amid proteasome dysfunction to facilitate the discovery of proteolytic pathways that are activated as a compensatory response to proteasome inhibition. Proteasome is a large multi-component proteolytic complex in the cell. It...
ORGANISM(S): Homo sapiens 
2009-01-27 | E-GEOD-14429 | biostudies-arrayexpress
Sort   by:  
 Page size